| Primary |
| Hypertension |
27.3% |
| Product Used For Unknown Indication |
27.3% |
| Type 2 Diabetes Mellitus |
18.2% |
| Cardiac Failure Congestive |
9.1% |
| Drug Use For Unknown Indication |
9.1% |
| Prophylaxis |
9.1% |
|
| Coronary Artery Disease |
20.0% |
| Dizziness |
20.0% |
| Pharmaceutical Product Complaint |
20.0% |
| Renal Failure Acute |
20.0% |
| Urticaria |
20.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
23.9% |
| Breast Cancer |
22.5% |
| Hypertension |
16.9% |
| Cardiac Failure Congestive |
8.5% |
| Coronary Artery Disease |
4.2% |
| Myocardial Ischaemia |
4.2% |
| Cerebrovascular Accident Prophylaxis |
2.8% |
| Chest Pain |
2.8% |
| Blood Cholesterol |
1.4% |
| Cardiac Disorder |
1.4% |
| Depression |
1.4% |
| Essential Hypertension |
1.4% |
| Glomerulonephritis Chronic |
1.4% |
| Gout |
1.4% |
| Metabolic Disorder |
1.4% |
| Prophylaxis |
1.4% |
| Sleep Disorder |
1.4% |
| Type 2 Diabetes Mellitus |
1.4% |
|
| Hepatitis Fulminant |
23.5% |
| Renal Failure Acute |
17.6% |
| Respiratory Distress |
11.8% |
| Coronary Artery Disease |
5.9% |
| Death |
5.9% |
| Drug Ineffective |
5.9% |
| Hepatitis |
5.9% |
| Hypotension |
5.9% |
| Loss Of Consciousness |
5.9% |
| Skin Discolouration |
5.9% |
| Vascular Occlusion |
5.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
32.9% |
| Drug Use For Unknown Indication |
19.4% |
| Hypertension |
10.7% |
| Prophylaxis |
4.3% |
| Cardiac Disorder |
3.7% |
| Cardiac Failure |
3.4% |
| Diabetes Mellitus |
3.2% |
| Coronary Artery Bypass |
2.7% |
| Pain |
2.4% |
| Cardiac Failure Chronic |
2.1% |
| Rheumatoid Arthritis |
2.0% |
| Chronic Obstructive Pulmonary Disease |
1.9% |
| Atrial Fibrillation |
1.7% |
| Type 2 Diabetes Mellitus |
1.7% |
| Angina Pectoris |
1.7% |
| Multiple Myeloma |
1.4% |
| Chest Pain |
1.3% |
| Nuclear Magnetic Resonance Imaging Brain |
1.2% |
| Osteoporosis |
1.2% |
| Arthritis |
1.0% |
|
| Vomiting |
11.1% |
| Urinary Tract Infection |
8.3% |
| Thrombocytopenia |
7.9% |
| Myocardial Infarction |
7.1% |
| Weight Decreased |
6.3% |
| Death |
6.0% |
| Pain |
6.0% |
| Renal Failure Acute |
4.8% |
| Injury |
4.4% |
| Pneumonia |
4.4% |
| Weight Increased |
4.4% |
| Dyspnoea |
4.0% |
| Fatigue |
3.6% |
| Renal Failure |
3.6% |
| Syncope |
3.6% |
| Anxiety |
3.2% |
| Type 2 Diabetes Mellitus |
3.2% |
| Drug Ineffective |
2.8% |
| Respiratory Failure |
2.8% |
| Rheumatoid Arthritis |
2.8% |
|
| Interacting |
| Erectile Dysfunction |
50.0% |
| Pain |
50.0% |
|
| Drug Interaction |
33.3% |
| Loss Of Consciousness |
33.3% |
| Pallor |
33.3% |
|
